Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF.

J Clin Invest. 2008 Oct;118(10):3420-30. doi: 10.1172/JCI36030.

2.

Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis.

Matsushita T, Horikawa M, Iwata Y, Tedder TF.

J Immunol. 2010 Aug 15;185(4):2240-52. doi: 10.4049/jimmunol.1001307. Epub 2010 Jul 12.

3.

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS.

Ann Neurol. 2010 Sep;68(3):369-83. doi: 10.1002/ana.22081.

4.

B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.

Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, Tisch RM, Tedder TF.

J Immunol. 2008 Mar 1;180(5):2863-75.

5.

Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis.

Matejuk A, Bakke AC, Hopke C, Dwyer J, Vandenbark AA, Offner H.

J Neurosci Res. 2004 Jul 1;77(1):119-26.

PMID:
15197745
6.

CD43 modulates severity and onset of experimental autoimmune encephalomyelitis.

Ford ML, Onami TM, Sperling AI, Ahmed R, Evavold BD.

J Immunol. 2003 Dec 15;171(12):6527-33.

7.

Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system.

Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, Merkler D, Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Brück W, Kalinke U.

Immunity. 2008 May;28(5):675-86. doi: 10.1016/j.immuni.2008.03.011.

8.
9.

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, Kuchroo VK, Miller SD.

J Clin Invest. 2001 Apr;107(8):995-1006.

12.

CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis.

Teige A, Teige I, Lavasani S, Bockermann R, Mondoc E, Holmdahl R, Issazadeh-Navikas S.

J Immunol. 2004 Jan 1;172(1):186-94.

13.

T-cell trafficking competence is required for CNS invasion.

Lees JR, Archambault AS, Russell JH.

J Neuroimmunol. 2006 Aug;177(1-2):1-10. Epub 2006 Jul 5.

PMID:
16822552
14.
15.

Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis.

van Zwam M, Huizinga R, Heijmans N, van Meurs M, Wierenga-Wolf AF, Melief MJ, Hintzen RQ, 't Hart BA, Amor S, Boven LA, Laman JD.

J Pathol. 2009 Mar;217(4):543-51. doi: 10.1002/path.2476.

PMID:
19023878
16.

LF 15-0195 treatment protects against central nervous system autoimmunity by favoring the development of Foxp3-expressing regulatory CD4 T cells.

Duplan V, Beriou G, Heslan JM, Bruand C, Dutartre P, Mars LT, Liblau RS, Cuturi MC, Saoudi A.

J Immunol. 2006 Jan 15;176(2):839-47.

17.

Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.

Selmaj K, Raine CS, Cross AH.

Ann Neurol. 1991 Nov;30(5):694-700.

PMID:
1722388
18.
19.

Experimental allergic encephalomyelitis (EAE) in mice lacking CD4+ T cells.

Koh DR, Ho A, Rahemtulla A, Penninger J, Mak TW.

Eur J Immunol. 1994 Sep;24(9):2250-3.

PMID:
7916298

Supplemental Content

Support Center